CD22 and neoplasm: Whereas marginal dose treatment of m971-scFv CAR-T again led to lower tumor signal than 1ug36 CD22sdCAR-T-treated mice, lymphoma growth was blocked completely in mice treated with a high dose of either CD22 CAR-T product (Figures 6A, 6B, and S12A).